Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

14.46
+0.07000.49%
Post-market: 14.460.00000.00%19:08 EDT
Volume:2.79M
Turnover:40.10M
Market Cap:1.48B
PE:-1.57
High:14.63
Open:14.48
Low:13.87
Close:14.39
Loading ...

Stock Track | Biohaven Pharmaceutical Plummets 14.50% as FDA Extends Review of Key Drug Application

Stock Track
·
16 May

BUZZ-U.S. STOCKS ON THE MOVE-Xponential Fitness, Phillips 66, Amazon.com

Reuters
·
16 May

Biohaven falls -17.0%

TIPRANKS
·
15 May

Biohaven Shares Slide 20.3% After US FDA Extends Review of Co's Genetic Disease Drug

THOMSON REUTERS
·
15 May

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday

MT Newswires Live
·
15 May

BUZZ-U.S. STOCKS ON THE MOVE-Deere, Lockheed Martin, Alibaba.com

Reuters
·
15 May

Deutsche Bank Trims Biohaven Price Target to $37 From $38, Maintains Buy Rating

MT Newswires Live
·
15 May

Biohaven Ltd. : Deutsche Bank Cuts Target Price to $37 From $38

THOMSON REUTERS
·
15 May

Stock Track | Biohaven Pharmaceutical Plunges 10.43% Pre-market as FDA Delays Decision on Key Drug

Stock Track
·
15 May

BUZZ-Biohaven drops after FDA extends review period for genetic disease drug

Reuters
·
15 May

Biohaven Shares Slide 11.5% Premarket After US FDA Extends Review of Co's Neurological Disorder Drug

THOMSON REUTERS
·
15 May

Biohaven Says FDA Committee Extended PDUFA Date for Troriluzole

MT Newswires Live
·
15 May

Stock Track | Biohaven Pharmaceutical Plunges 6.36% as FDA Extends Review of Key Drug Application

Stock Track
·
15 May

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

Dow Jones
·
15 May

Stock Track | Biohaven Plunges 5.90% After-Hours as FDA Extends Review of Key Drug Application

Stock Track
·
15 May

FDA extends PDUFA for Biohaven’s Troriluzole new drug application

TIPRANKS
·
15 May

BRIEF-Biohaven Says FDA Extends PDUFA Date Of Biohaven's Troriluzole NDA For Rare Disease Spinocerebellar Ataxia

Reuters
·
15 May

Biohaven Ltd. Announces FDA Extends PDUFA Date for Troriluzole NDA Review for Rare Disease Spinocerebellar Ataxia

Reuters
·
15 May

Biohaven Ltd - FDA's Decision Regarding Nda Is NOW Expected in 4Q 2025.

THOMSON REUTERS
·
15 May

FDA Extends Pdufa Date of Biohaven's Troriluzole Nda for Rare Disease Spinocerebellar Ataxia

THOMSON REUTERS
·
15 May